Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
TBPH Stock Chart & Stats
$14.17
-$0.06(-0.65%)
At close: 4:00 PM EST
$14.17
-$0.06(-0.65%)
Day’s Range― - ―
52-Week Range$7.90 - $15.15
Previous CloseN/A
Volume28.33K
Average Volume (3M)306.36K
Market Cap
$713.62M
Enterprise Value$267.16M
Total Cash (Recent Filing)$338.80M
Total Debt (Recent Filing)$46.46M
Price to Earnings (P/E)60.6
Beta1.00
Next Earnings
Nov 10, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.08
Shares Outstanding50,361,298
10 Day Avg. Volume243,260
30 Day Avg. Volume306,359
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)2.62
Price to Sales (P/S)7.14
P/FCF Ratio-38.73
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda5.80
Forecast
1Y Price Target
$20.00Price Target Upside41.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommendation is a 'Buy' for Theravance Biopharma stock with a price target of 24.00.
Clinical Trial SuccessThe CYPRESS trial is significantly de-risked by preceding Phase 3 results where ampreloxetine showed positive trends without worsening of supine hypertension.
Market PotentialA large majority of MSA patients with neurogenic orthostatic hypotension require pharmacologic treatment, indicating a strong market need.
Bears Say
Theravance Biopharma News
TBPH FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was $7.90 and its highest was $15.15 in the past 12 months.
What is Theravance Biopharma’s market cap?
Theravance Biopharma’s market cap is $713.62M.
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Nov 10, 2025 which is in 11 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on Aug 12, 2025. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.673 by $0.407.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is -0.13.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 50,361,298 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of $1.08 in its last earnings report, beating expectations of $0.673. Following the earnings report the stock price went up 4.195%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Currently, no hedge funds are holding shares in TBPH
Theravance Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (41.14% Upside)
$20.00 (41.14% Upside)
Blogger Sentiment
Bearish
TBPH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 22.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 5.7%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.77%
12-Months-Change
Fundamentals
Return on Equity
6.23%
Trailing 12-Months
Asset Growth
17.68%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing innovative medicines for serious illnesses, particularly in the areas of respiratory and gastrointestinal diseases. The company operates primarily in the pharmaceutical sector, with a portfolio that includes a range of products designed to address unmet medical needs. Its lead product, Vibativ (telavancin), is an injectable antibiotic used for the treatment of certain infections, and the company is actively engaged in the research and development of novel therapeutics targeting various conditions.
TBPH Company Deck
TBPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased a strong financial performance with significant growth in YUPELRI sales and strategic financial transactions that bolster Theravance's balance sheet. The advancement of the ampreloxetine trial and strong TRELEGY performance add to the positive outlook. However, uncertainties around YUPELRI's launch in China and tax liabilities from recent transactions were noted as slight concerns.View all TBPH earnings summariesTBPH Stock 12 Month Forecast
Average Price Target
$20.00
▲(41.14% Upside)
Technical Analysis
Anavex Life Sciences
―
Maravai Lifesciences Holdings
―
Terns Pharmaceuticals
―
Nanobiotix
―
Day One Biopharmaceuticals
―
Ownership Overview
7.04% Insiders
8.71% Mutual Funds
0.98% Other Institutional Investors
73.64% Public Companies and
Individual Investors